Intratumoral LAK cell and interleukin-2 therapy of human gliomas

View More View Less
  • 1 Clinical Neurosurgery Section, Surgical Neurology Branch, National Institute of Neurological and Communicative Disorders and Stroke, and Surgery Branch, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

✓ Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) offers the possibility of a new treatment for patients with malignant glial tumors. In a clinical trial, the effectiveness of a 5-day treatment cycle of direct intratumoral administration of both LAK cells and IL-2 via a reservoir/catheter system in patients with recurrent malignant gliomas was studied. Ten patients were entered into the study, nine of whom were treated with 15 cycles of LAK cells (0.9 to 21.0 × 109 cells) and IL-2 (49 to 450 × 103 U/kg). The 10th patient in the study was not treated because of the onset of severe neurological deficits prior to beginning immunotherapy. Of the nine patients treated, one had a partial tumor response to immunotherapy as documented by computerized tomography. Neurological side effects occurred in all patients undergoing treatment and were related to increases in cerebral edema that appeared to be mediated by the immunotherapy. This report demonstrates the present limitations of regional adoptive immunotherapy with LAK cells and IL-2 in the treatment of human glial tumors.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Address reprint requests to: David Barba, M.D., Division of Neurosurgery, University of California at San Diego Medical Center, H-893, 225 Dickinson Street, San Diego, California 92103.
  • 1.

    Alexander JT, , Saris SC, & Oldfield EH: The effect of interleukin-2 on the blood-brain barrier in the 9L gliosarcoma rat model. J Neurosurg 70:9296, 1989 Alexander JT, Saris SC, Oldfield EH: The effect of interleukin-2 on the blood-brain barrier in the 9L gliosarcoma rat model. J Neurosurg 70:92–96, 1989

    • Search Google Scholar
    • Export Citation
  • 2.

    Bloom HJG, , Peckham MJ, & Richardson AE, et al: Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy. Br J Cancer 27:253267, 1973 Bloom HJG, Peckham MJ, Richardson AE, et al: Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy. Br J Cancer 27:253–267, 1973

    • Search Google Scholar
    • Export Citation
  • 3.

    Brooks WH, , Caldwell HD, & Mortara RH: Immune responses in patients with gliomas. Surg Neurol 2:419423, 1974 Brooks WH, Caldwell HD, Mortara RH: Immune responses in patients with gliomas. Surg Neurol 2:419–423, 1974

    • Search Google Scholar
    • Export Citation
  • 4.

    Burger PC, , Dubois PJ, & Schold SC, et al: Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58:159169, 1983 Burger PC, Dubois PJ, Schold SC, et al: Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58:159–169, 1983

    • Search Google Scholar
    • Export Citation
  • 5.

    Donohue JH, & Rosenberg SA: The fate of interleukin-2 after in vivo administration. J Immunol 130:22032208, 1980 Donohue JH, Rosenberg SA: The fate of interleukin-2 after in vivo administration. J Immunol 130:2203–2208, 1980

    • Search Google Scholar
    • Export Citation
  • 6.

    Ellison MD, , Povlishock JT, & Merchant RE: Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusion. Cancer Res 47:57655770, 1987 Ellison MD, Povlishock JT, Merchant RE: Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusion. Cancer Res 47:5765–5770, 1987

    • Search Google Scholar
    • Export Citation
  • 7.

    Fontana A, , Hengartner H, & de Tribolet N, et al: Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 132:18371844, 1984 Fontana A, Hengartner H, de Tribolet N, et al: Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 132:1837–1844, 1984

    • Search Google Scholar
    • Export Citation
  • 8.

    Grimm EA, , Mazumder A, & Zhang HZ, et al: Lymphokineactivated killer cell phenomenon. Lysis of natural killerresistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:18231841, 1982 Grimm EA, Mazumder A, Zhang HZ, et al: Lymphokineactivated killer cell phenomenon. Lysis of natural killerresistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841, 1982

    • Search Google Scholar
    • Export Citation
  • 9.

    Grimm EA, , Muul LM, & Wilson DJ: The differential inhibitory effects exerted by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin-2 versus allospecific CTL. Transplantation 39:537540, 1985 Grimm EA, Muul LM, Wilson DJ: The differential inhibitory effects exerted by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin-2 versus allospecific CTL. Transplantation 39:537–540, 1985

    • Search Google Scholar
    • Export Citation
  • 10.

    Hook GR, , Greenwood MA, & Barba D, et al: The morphology of interleukin-2 stimulated human peripheral blood mononuclear cells killing glioma-derived cells in vitro. JNCI 80:171177, 1988 Hook GR, Greenwood MA, Barba D, et al: The morphology of interleukin-2 stimulated human peripheral blood mononuclear cells killing glioma-derived cells in vitro. JNCI 80:171–177, 1988

    • Search Google Scholar
    • Export Citation
  • 11.

    Ingram M, , Shelden CH, & Jacques S, et al: Preliminary clinical trial of immunotherapy for malignant glioma. J Biol Response Mod 6:489498, 1987 Ingram M, Shelden CH, Jacques S, et al: Preliminary clinical trial of immunotherapy for malignant glioma. J Biol Response Mod 6:489–498, 1987

    • Search Google Scholar
    • Export Citation
  • 12.

    Jacobs SK, , Wilson DJ, & Kornblith PL, et al: Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg 64:743749, 1986 Jacobs SK, Wilson DJ, Kornblith PL, et al: Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg 64:743–749, 1986

    • Search Google Scholar
    • Export Citation
  • 13.

    Jacobs SK, , Wilson DJ, & Kornblith PL, et al: In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J Neurosurg 64:114117, 1986 Jacobs SK, Wilson DJ, Kornblith PL, et al: In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J Neurosurg 64:114–117, 1986

    • Search Google Scholar
    • Export Citation
  • 14.

    Lotze MT, , Grimm EA, & Mazumder A, et al: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41:44204425, 1981 Lotze MT, Grimm EA, Mazumder A, et al: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41:4420–4425, 1981

    • Search Google Scholar
    • Export Citation
  • 15.

    Lotze MT, , Matory YL, & Ettinghausen SE, et al: In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135:28652875, 1985 Lotze MT, Matory YL, Ettinghausen SE, et al: In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135:2865–2875, 1985

    • Search Google Scholar
    • Export Citation
  • 16.

    Muul LM, , Director EP, & Hyatt CL, et al: Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. J Immunol Methods 88:265275, 1986 Muul LM, Director EP, Hyatt CL, et al: Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. J Immunol Methods 88:265–275, 1986

    • Search Google Scholar
    • Export Citation
  • 17.

    Neuwelt EA, , Clark K, & Kirkpatrick JB, et al: Clinical studies of intrathecal autologous lymphocyte infusions in patients with malignant glioma: a toxicity study. Ann Neurol 4:307312, 1978 Neuwelt EA, Clark K, Kirkpatrick JB, et al: Clinical studies of intrathecal autologous lymphocyte infusions in patients with malignant glioma: a toxicity study. Ann Neurol 4:307–312, 1978

    • Search Google Scholar
    • Export Citation
  • 18.

    Papa MZ, , Vetto JT, & Ettinghausen SE, et al: Effect of corticosteroid on the antitumor activity of lymphokineactivated killer cells and interleukin 2 in mice. Cancer Res 46:56185623, 1986 Papa MZ, Vetto JT, Ettinghausen SE, et al: Effect of corticosteroid on the antitumor activity of lymphokineactivated killer cells and interleukin 2 in mice. Cancer Res 46:5618–5623, 1986

    • Search Google Scholar
    • Export Citation
  • 19.

    Rosenberg SA: Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2, in Devita VT, , Hellman S, & Rosenberg SA (eds): Important Advances in Oncology. Philadelphia: JB Lippincott, 1986, pp 5591 Rosenberg SA: Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2, in Devita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia: JB Lippincott, 1986, pp 55–91

    • Search Google Scholar
    • Export Citation
  • 20.

    Rosenberg SA, , Grimm EA, & McGrogan M, et al: Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 223:14121415, 1984 Rosenberg SA, Grimm EA, McGrogan M, et al: Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 223:1412–1415, 1984

    • Search Google Scholar
    • Export Citation
  • 21.

    Rosenberg SA, , Lotze MT, & Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889897, 1987 Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897, 1987

    • Search Google Scholar
    • Export Citation
  • 22.

    Rosenberg SA, , Spiess P, & Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:13181321, 1986 Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318–1321, 1986

    • Search Google Scholar
    • Export Citation
  • 23.

    Rosenstein M, , Ettinghausen SE, & Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137:17351742, 1986 Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137:1735–1742, 1986

    • Search Google Scholar
    • Export Citation
  • 24.

    Schwyzer M, & Fontana A: Partial purification and biochemical characterization of a T cell suppressor factor produced by human glioblastoma cells. J Immunol 134:10031009, 1985 Schwyzer M, Fontana A: Partial purification and biochemical characterization of a T cell suppressor factor produced by human glioblastoma cells. J Immunol 134:1003–1009, 1985

    • Search Google Scholar
    • Export Citation
  • 25.

    Silverberg E, & Lubera J: Cancer statistics 1987. CA 37:219, 1987 Silverberg E, Lubera J: Cancer statistics 1987. CA 37:2–19, 1987

  • 26.

    Sobel AT, , Branellec AI, & Blanc JC, et al: Physicochemical characterization of a vascular permeability factor produced by Con A-stimulated human lymphocytes. J Immunol 119:12301234, 1977 Sobel AT, Branellec AI, Blanc JC, et al: Physicochemical characterization of a vascular permeability factor produced by Con A-stimulated human lymphocytes. J Immunol 119:1230–1234, 1977

    • Search Google Scholar
    • Export Citation
  • 27.

    Takakura K, , Miki Y, & Kubo O: Adjuvant immunotherapy for malignant brain tumors. Jpn J Clin Oncol 2:109120, 1972 Takakura K, Miki Y, Kubo O: Adjuvant immunotherapy for malignant brain tumors. Jpn J Clin Oncol 2:109–120, 1972

    • Search Google Scholar
    • Export Citation
  • 28.

    Takakura K, , Miki Y, & Kubo O, et al: Adjuvant immunotherapy for malignant brain tumors in infants and children. Childs Brain 1:141147, 1975 Takakura K, Miki Y, Kubo O, et al: Adjuvant immunotherapy for malignant brain tumors in infants and children. Childs Brain 1:141–147, 1975

    • Search Google Scholar
    • Export Citation
  • 29.

    Topalian SL, , Muul LM, & Solomon D, et al: Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102:127141, 1987 Topalian SL, Muul LM, Solomon D, et al: Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102:127–141, 1987

    • Search Google Scholar
    • Export Citation
  • 30.

    Trouillas P: Immunologie et immunothérapie des tumeurs cérébrales. État actuel. Rev Neurol 128:2338, 1973 Trouillas P: Immunologie et immunothérapie des tumeurs cérébrales. État actuel. Rev Neurol 128:23–38, 1973

    • Search Google Scholar
    • Export Citation
  • 31.

    Vetto JT, , Papa MZ, & Lotze MT, et al: Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 5:496503, 1987 Vetto JT, Papa MZ, Lotze MT, et al: Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 5:496–503, 1987

    • Search Google Scholar
    • Export Citation
  • 32.

    Young H, , Kaplan A, & Regelson W: Immunotherapy with autologous white cell infusions (“lymphocytes”) in the treatment of recurrent glioblastoma multiforme. A preliminary report. Cancer 40:10371044, 1977 Young H, Kaplan A, Regelson W: Immunotherapy with autologous white cell infusions (“lymphocytes”) in the treatment of recurrent glioblastoma multiforme. A preliminary report. Cancer 40:1037–1044, 1977

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 294 123 3
Full Text Views 164 5 0
PDF Downloads 97 5 0
EPUB Downloads 0 0 0